These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 24378999)

  • 41. Efficacy and safety of the treatment: combination of benazepril/lercanidipine vs. benazepril alone in patients with mild-to-moderate hypertension.
    Chen T; Chen GH; Yang TS; Zhong ZY; An WS; Zhang XX; Li JD
    Chin Med J (Engl); 2013 Jun; 126(12):2286-90. PubMed ID: 23786940
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fixed combinations in the management of hypertension: perspectives on lercanidipine-enalapril.
    Barrios V; Escobar C; Echarri R
    Vasc Health Risk Manag; 2008; 4(4):847-53. PubMed ID: 19066001
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dose-response effect of the lercanidipine/enalapril combination: a pooled analysis.
    Rizzoni D
    Curr Med Res Opin; 2016 Oct; 32(sup2):17-23. PubMed ID: 27779458
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of effects of enalapril and nitrendipine on cardiac sympathetic nervous system in essential hypertension.
    Sakata K; Shirotani M; Yoshida H; Kurata C
    J Am Coll Cardiol; 1998 Aug; 32(2):438-43. PubMed ID: 9708473
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lercanidipine: a review of its use in hypertension.
    McClellan KJ; Jarvis B
    Drugs; 2000 Nov; 60(5):1123-40. PubMed ID: 11129125
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lercanidipine : a review of its efficacy in the management of hypertension.
    Bang LM; Chapman TM; Goa KL
    Drugs; 2003; 63(22):2449-72. PubMed ID: 14609358
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Influence of race and dietary salt on the antihypertensive efficacy of an angiotensin-converting enzyme inhibitor or a calcium channel antagonist in salt-sensitive hypertensives.
    Weir MR; Chrysant SG; McCarron DA; Canossa-Terris M; Cohen JD; Gunter PA; Lewin AJ; Mennella RF; Kirkegaard LW; Hamilton JH; Weinberger MH; Weder AB
    Hypertension; 1998 May; 31(5):1088-96. PubMed ID: 9576119
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antihypertensive treatment with calcium channel blockers and renal protection: focus on lercanidipine and lercanidipine/enalapril.
    Ferri N; Corsini A; Pontremoli R
    Eur Rev Med Pharmacol Sci; 2022 Oct; 26(20):7482-7492. PubMed ID: 36314318
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Evaluation of the safety and efficacy of the lisinopril + hydrochlorothiazide and captopril + hydrochlorothiazide combinations in the treatment of essential arterial hypertension].
    Rappelli A; Ambrosio GB; Caiazza A; Labriola E; Maiorano G; Pretolani E; Porcellati C; Pupita F; Saba P; Stornello M
    Minerva Med; 1992; 83(1-2):57-64. PubMed ID: 1312233
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pressure and microcirculatory effects of treatment with lercanidipine in hypertensive patients and in vascular patients with hypertension.
    Cesarone MR; Incandela L; Ledda A; De Sanctis MT; Steigerwalt R; Pellegrini L; Bucci M; Belcaro G; Ciccarelli R
    Angiology; 2000 Aug; 51(8 Pt 2):S53-63. PubMed ID: 10959511
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.
    Shimada K; Ogihara T; Saruta T; Kuramoto K;
    Clin Ther; 2010 May; 32(5):861-81. PubMed ID: 20685495
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Vascular effects of the lercanidipine/enalapril combination: clinical relevance.
    Parati G
    Curr Med Res Opin; 2016 Oct; 32(sup2):25-28. PubMed ID: 27779459
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety evaluation of perindopril-lercanidipine combined therapy in patients with mild essential hypertension.
    Yang Z
    Curr Med Res Opin; 2015 Jan; 31(1):183-6. PubMed ID: 25424689
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Barnidipine compared to lercanidipine in addition to losartan on endothelial damage and oxidative stress parameters in patients with hypertension and type 2 diabetes mellitus.
    Derosa G; Mugellini A; Pesce RM; D'Angelo A; Maffioli P
    BMC Cardiovasc Disord; 2016 Apr; 16():66. PubMed ID: 27068332
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.
    Pitt B; Reichek N; Willenbrock R; Zannad F; Phillips RA; Roniker B; Kleiman J; Krause S; Burns D; Williams GH
    Circulation; 2003 Oct; 108(15):1831-8. PubMed ID: 14517164
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of manidipine/delapril versus losartan/hydrochlorothiazide fixed combinations in patients with hypertension and diabetes.
    Roca-Cusachs A; Schmieder RE; Triposkiadis F; Wenzel RR; Laurent S; Kohlmann O; Fogari R;
    J Hypertens; 2008 Apr; 26(4):813-8. PubMed ID: 18327093
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Heterogeneous effect of calcium antagonists on leg oedema: a comparison of amlodipine versus lercanidipine in hypertensive patients.
    Pedrinelli R; Dell'Omo G; Nuti M; Menegato A; Balbarini A; Mariani M
    J Hypertens; 2003 Oct; 21(10):1969-73. PubMed ID: 14508205
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Fixed-dose lercanidipine/enalapril for hypertension.
    Menne J; Haller H
    Drugs Today (Barc); 2008 Apr; 44(4):261-70. PubMed ID: 18536784
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of quinapril, quinapril-hydrochlorothiazide, and enalapril on the bone mass of hypertensive subjects: relationship with angiotensin converting enzyme polymorphisms.
    Pérez-Castrillón JL; Silva J; Justo I; Sanz A; Martín-Luquero M; Igea R; Escudero P; Pueyo C; Díaz C; Hernández G; Dueñas A
    Am J Hypertens; 2003 Jun; 16(6):453-9. PubMed ID: 12799093
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lercanidipine valuable effect on urine protein losses: the RED LEVEL study.
    Robles NR; Calvo C; Sobrino J; Espinel E; Esteban R; Mateos L; Macias JF
    Curr Med Res Opin; 2016 Oct; 32(sup2):29-34. PubMed ID: 27779460
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.